Parkinson Disease
Item
diagnosis of idiopathic pd (icd9=332.0)
boolean
C0030567 (UMLS CUI [1])
Mini-mental state examination | Informed Consent | Questionnaires Completion | Maintain voiding diary
Item
mmse 24, able to give informed consent and complete questionnaires and voiding diaries.
boolean
C0451306 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
C0034394 (UMLS CUI [3,1])
C0205197 (UMLS CUI [3,2])
C3161951 (UMLS CUI [4])
Work up Urologic
Item
urological work-up within 3 months of enrollment to:
boolean
C0750430 (UMLS CUI [1,1])
C0042077 (UMLS CUI [1,2])
Rule out Causes Reversible Urinary symptoms
Item
rule out treatable causes of urinary symptoms
boolean
C0332196 (UMLS CUI [1,1])
C0015127 (UMLS CUI [1,2])
C0205343 (UMLS CUI [1,3])
C0426359 (UMLS CUI [1,4])
Urinalysis
Item
urinalysis (ua)
boolean
C0042014 (UMLS CUI [1])
Ultrasound PVR
Item
post-void residual ultrasound (pvr)
boolean
C2052173 (UMLS CUI [1])
Cytology urinary
Item
urinary cytology
boolean
C0010818 (UMLS CUI [1,1])
C1524119 (UMLS CUI [1,2])
Symptoms Overactive Bladder
Item
documented symptoms oab on screening 3-day voiding diary:
boolean
C1457887 (UMLS CUI [1,1])
C0878773 (UMLS CUI [1,2])
Urgency Episode Quantity per day
Item
average of 1 urgency episode / 24 hours, and
boolean
C0085606 (UMLS CUI [1,1])
C0332189 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0439505 (UMLS CUI [1,4])
Urination Quantity per day
Item
average of 8 micturitions / 24 hours
boolean
C0042034 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0439505 (UMLS CUI [1,3])
Complaints Symptoms Duration
Item
subjective complaints of symptoms for 3 months
boolean
C3469071 (UMLS CUI [1,1])
C1457887 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
Exposure to Anticholinergic Agents | Exposure to Antispasmodics | Atropine | tolterodine | Benztropine | Trihexyphenidyl | Dicyclomine | Hyoscyamine | Scopolamine
Item
exposure to anticholinergics or antispasmodics within the last 4 weeks (among them: atropine, tolterodine, benztropine, trihexyphenidyl, dicyclomine, hyoscyamine, and scopolamine)
boolean
C0332157 (UMLS CUI [1,1])
C0242896 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C0037766 (UMLS CUI [2,2])
C0004259 (UMLS CUI [3])
C0388753 (UMLS CUI [4])
C0005098 (UMLS CUI [5])
C0041009 (UMLS CUI [6])
C0012125 (UMLS CUI [7])
C0596004 (UMLS CUI [8])
C0036442 (UMLS CUI [9])
Exposure to Pharmaceutical Preparations Affecting Cognition | Opioids | Benzodiazepines | Sedating antihistamine
Item
exposure to drugs with known effects on cognition (i.e. opioids, benzodiazepines or sedating antihistamines) within the last week
boolean
C0332157 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0392760 (UMLS CUI [1,3])
C0009240 (UMLS CUI [1,4])
C0242402 (UMLS CUI [2])
C0005064 (UMLS CUI [3])
C1955826 (UMLS CUI [4])
Exposure to Pharmaceutical Preparations Contraindicated | Pharmaceutical Preparations Use of Cytochrome P450 | Pharmaceutical Preparations Use of Cytochrome P-450 CYP3A4 | Ketoconazole | Itraconazole | Miconazole | Erythromycin | Clarithromycin | Ritonavir | Nelfinavir | nefazodone | Flecainide | Thioridazine | Tricyclic Antidepressive Agents
Item
exposure to drugs contraindicated or cautioned in use with the 2 study medications (drugs that also use the cytochrome p450 enzyme, primarily cyp3a4). these include: ketoconazole, itraconazole, miconazole, erythromycin, clarithromycin, ritonavir, nelfinavir, nefazodone, flecainide, thioridazine and tricyclic antidepressants.
boolean
C0332157 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C1444657 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
C0010762 (UMLS CUI [2,3])
C0013227 (UMLS CUI [3,1])
C1524063 (UMLS CUI [3,2])
C3714798 (UMLS CUI [3,3])
C0022625 (UMLS CUI [4])
C0064113 (UMLS CUI [5])
C0025942 (UMLS CUI [6])
C0014806 (UMLS CUI [7])
C0055856 (UMLS CUI [8])
C0292818 (UMLS CUI [9])
C0525005 (UMLS CUI [10])
C0068485 (UMLS CUI [11])
C0016229 (UMLS CUI [12])
C0039943 (UMLS CUI [13])
C0003290 (UMLS CUI [14])
Therapeutic procedure Overactive Bladder | Exception Pharmacotherapy | Biofeedback | Physical therapy | Acupuncture procedure
Item
nonpharmacological treatment of oab within the last 4 weeks (for example: biofeedback, physical therapy, acupuncture)
boolean
C0087111 (UMLS CUI [1,1])
C0878773 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0013216 (UMLS CUI [2,2])
C0005491 (UMLS CUI [3])
C0949766 (UMLS CUI [4])
C0394664 (UMLS CUI [5])
Angle Closure Glaucoma Uncontrolled
Item
uncontrolled narrow angle glaucoma
boolean
C0017605 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Gastric retention | Urinary Retention | Dysmotility of stomach | Dysmotility urinary | Ulcerative Colitis | Myasthenia Gravis | Severe constipation
Item
history of gastric or urinary retention / dysmotility (ulcerative colitis, myasthenia gravis and severe constipation)
boolean
C0585136 (UMLS CUI [1])
C0080274 (UMLS CUI [2])
C0431579 (UMLS CUI [3])
C0679316 (UMLS CUI [4,1])
C1524119 (UMLS CUI [4,2])
C0009324 (UMLS CUI [5])
C0026896 (UMLS CUI [6])
C1855664 (UMLS CUI [7])
Hepatic impairment | Renal Insufficiency
Item
history of hepatic or renal impairment
boolean
C0948807 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
Severe gastroesophageal reflux | Diphosphonates | Patients At risk Esophagitis
Item
history of severe gastro-esophageal reflux disease and/or use of bisphosphonates, patients at risk for esophagitis
boolean
C1857946 (UMLS CUI [1])
C0012544 (UMLS CUI [2])
C0030705 (UMLS CUI [3,1])
C1444641 (UMLS CUI [3,2])
C0014868 (UMLS CUI [3,3])
Exposure to Anticholinergic Agents | Anticholinergic Agents Symptoms Overactive Bladder | Symptoms Overactive Bladder Resulting in Adverse effects | Adverse effects Causing Medication stop
Item
previous exposure to anticholinergic for oab symptoms that resulted in side effects that caused cessation of the medication
boolean
C0332157 (UMLS CUI [1,1])
C0242896 (UMLS CUI [1,2])
C0242896 (UMLS CUI [2,1])
C1457887 (UMLS CUI [2,2])
C0878773 (UMLS CUI [2,3])
C1457887 (UMLS CUI [3,1])
C0878773 (UMLS CUI [3,2])
C0332294 (UMLS CUI [3,3])
C0879626 (UMLS CUI [3,4])
C0879626 (UMLS CUI [4,1])
C0678227 (UMLS CUI [4,2])
C0850893 (UMLS CUI [4,3])